Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;20(11):1229-39.
doi: 10.1089/hum.2009.142.

Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?"

Gianpietro Dotti  1 , Barbara Savoldo, Malcolm Brenner
Affiliations
Review

Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?"

Gianpietro Dotti et al. Hum Gene Ther. 2009 Nov.

Abstract

"T-body" or chimeric antigen receptor (CAR) technology, which combines the specificity of an antibody with the homing, tissue penetration, and target cell destruction of T cells, was first described in 1993. After many years of unmet promise, significant improvements in gene transfer, including the development of efficient retroviral vectors for transduction of human T cells, and better understanding of immunological pathways and immune cell interactions, are allowing this technology to reach a critical phase of evaluation, in which we will learn whether the approach can truly meet expectations. In this review we summarize the concept of CAR-based immunotherapy, describe the steps accomplished, and outline the future progress we need to make if this approach is truly to improve cancer immunotherapy.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Methods to Overcome Tumor Immune Evasion
FIG. 2.
FIG. 2.
Methods to Overcome Tumor Immune Evasion
See this image and copyright information in PMC

References

    1. Ahmadzadeh M. Rosenberg S.A. IL-2 administration increases CD4+ CD25hi Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409–2414. - PMC - PubMed
    1. Ahmed N. Ratnayake M. Savoldo B. Perlaky L. Dotti G. Wels W.S. Bhattacharjee M.B. Gilbertson R.J. Shine H.D. Weiss H.L. Rooney C.M. Heslop H.E. Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67:5957–5964. - PubMed
    1. Alpdogan O. Muriglan S.J. Eng J.M. Willis L.M. Greenberg A.S. Kappel B.J. van den Brink M.R. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 2003;112:1095–1107. - PMC - PubMed
    1. Andorsky D.J. Timmerman J.M. Interleukin-21: Biology and application to cancer therapy. Expert Opin. Biol. Ther. 2008;8:1295–1307. - PubMed
    1. Berger C. Jensen M.C. Lansdorp P.M. Gough M. Elliott C. Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 2008;118:294–305. - PMC - PubMed

Publication types

Substances